SCHEMBL362079

SCHEMBL362079

O=C1[N]C=Nc2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.36
MEN1 O00255 5/20 0.36
CDC25B P30305 2/20 0.36
MAPT P10636 4/20 0.35
MAOA P21397 3/20 0.35
APAF1 O14727 3/20 0.35
POLB P06746 2/20 0.35
TDP2 O95551 2/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 2/20 0.35
GALK1 P51570 2/20 0.35
CES2 O00748 1/20 0.35
TERT O14746 1/20 0.35
NPC1 O15118 1/20 0.35
PLIN1 O60240 1/20 0.35
S1PR4 O95977 1/20 0.35
PLA2G1B P04054 1/20 0.35
BCHE P06276 1/20 0.35
PTPRC P08575 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332780 0.82 GSK3B (0.37) KMT2AMEN1CDC25BMAPTMAOA
SCHEMBL28158855 0.82 GSK3B (0.37) KMT2AMEN1CDC25BMAPTMAOA
SCHEMBL7921203 0.70
SCHEMBL2863 0.69
SCHEMBL94097 0.69 MEN1 (0.41) KMT2AMEN1CDC25BMAPTMAOA
SCHEMBL2515396 0.68 MAOA (0.32) KMT2AMEN1CDC25BMAPTMAOA
SCHEMBL7831389 0.68
SCHEMBL5712063 0.67 TRPA1 (0.30)
SCHEMBL21797450 0.67 PIM1 (0.38) MAOALMNAMAPK1MAOBALDH1A1
SCHEMBL1497963 0.67 CDC25B (0.42) KMT2AMEN1CDC25BMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-111132974-B Sulfonamide carboxamide compounds 英夫拉索姆有限公司 2023-11-21 CN claimed
CN-107108583-B Indole carboxamide compounds useful as kinase inhibitors 百时美施贵宝公司 2020-11-13 CN claimed
US-10604504-B2 Indole carboxamide compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2020-03-31 US claimed
US-20190248760-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2019-08-15 US claimed
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL MYERS SQUIBB CO (US) 2017-09-14 US claimed
EP-3209656-A1 INDOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2017-08-30 EP claimed
EP-3154969-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2017-04-19 EP claimed
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BRISTOL-MYERS SQUIBB COMPANY 2016-04-28 US claimed
WO-2015191745-A1 PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS GILEAD SCIENCES, INC. (US) 2015-12-17 WO claimed
US-20080255147-A1 Heterocycles useful as modulators of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2008-10-16 US claimed
WO-2006130493-A2 HETEROCYCLES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-12-07 WO claimed
US-20050272931-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-12-08 US claimed
EP-1463714-A4 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC (US) 2005-10-19 EP claimed
US-20050227986-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2005-10-13 US claimed
EP-1463714-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS Amgen Inc. (US) 2004-10-06 EP claimed
US-20030195201-A1 Vanilloid receptor ligands and their use in treatments AMGEN INC. 2003-10-16 US claimed
WO-2003049702-A2 VANILLOID RECEPTOR LIGANDS AND THEIR USE IN TREATMENTS AMGEN INC. (US) 2003-06-19 WO claimed
EP-0561357-A1 Pharmaceutical composition comprising a potassium-channel-opener and an antagonist of angiotensin-II receptors MERCK PATENT GmbH (DE) 1993-09-22 EP claimed
EP-0401505-A2 Pharmaceutical composition containing a potassium channel-activator and an ace-inhibitor MERCK PATENT GmbH (DE) 1990-12-12 EP claimed
EP-0346724-A1 Chroman derivates MERCK PATENT GmbH (DE) 1989-12-20 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050272931-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KMT2A 3777/4885MEN1 3504/4885CDC25B 3717/4885
US-20030195201-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KMT2A 3770/4885MEN1 3327/4885CDC25B 3926/4885
US-20190248760-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 KMT2A 1208/4885MEN1 2447/4885CDC25B 1499/4885
US-20050227986-A1 Vanilloid receptor ligands and their use in treatments TRPV1, TRPV2, TRPV3 KMT2A 3777/4885MEN1 3504/4885CDC25B 3717/4885
US-20170260160-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 KMT2A 1208/4885MEN1 2447/4885CDC25B 1499/4885
US-20080255147-A1 Heterocycles useful as modulators of ion channels KCNJ2, TRPV1, KCNJ1 KMT2A 3189/4885MEN1 1502/4885CDC25B 1700/4885
US-20160115126-A1 INDOLE CARBOXAMIDE COMPOUNDS BTK, JAK2, BRD4 KMT2A 1208/4885MEN1 2447/4885CDC25B 1499/4885
US-10604504-B2 Indole carboxamide compounds BTK, JAK2, BRD4 KMT2A 1208/4885MEN1 2447/4885CDC25B 1499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.